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Abstract Following the approval of the U.S. Food and
Drug Administration (FDA), high field magnetic resonance
imaging (MRI) has been increasingly incorporated into the
clinical setting. Especially in the field of neuroimaging, the
number of high field MRI applications has been increased
dramatically. Taking advantage on increased signal-to-noise
ratio (SNR) and chemical shift, higher magnetic field
strengths offer new perspectives particularly in brain
imaging and also challenges in terms of several technical
and physical consequences. Over the past few years, many
applications of high field MRI in patients with suspected
and definite multiple sclerosis (MS) have been reported
including conventional and quantitative MRI methods.
Conventional pulse sequences at 3 T offers higher lesion
detection rates when compared to 1.5 T, particularly in
anatomic regions which are important for the diagnosis of
patients with MS. MR spectroscopy at 3 T is characterized
by an improved spectral resolution due to increased
chemical shift allowing a better quantification of metabo-
lites. It detects significant axonal damage already in
patients presenting with clinically isolated syndromes and
can quantify metabolites of special interest such as
glutamate which is technically difficult to quantify at lower
field strengths. Furthermore, the higher susceptibility and
SNR offer advantages in the field of functional MRI and
diffusion tensor imaging. The recently introduced new
generation of ultra-high field systems beyond 3 T allows
scanning in submillimeter resolution and gives new insights
into in vivo MS pathology on MRI. The objectives of this
article are to review the current knowledge and level of
evidence concerning the application of high field MRI in
MS and to give some ideas of research perspectives in the
future.
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Introduction
Multiple sclerosis (MS) is the most common chronic
inflammatory disease of the central nervous system (CNS)
in young adults with a prevalence of 1:1,000 people in
Europe [1]. Pathologically, MS is a heterogenic chronic
immune-mediated inflammatory disorder of the CNS
disseminated in space and in time which is characterized
by focal and diffuse areas of demyelination within the white
and gray matter associated with axonal damage and loss
[2]. Magnetic resonance imaging (MRI) is the most
sensitive diagnostic tool in the detection of focal and
diffuse changes of MS in vivo and has become the most
important paraclinical method in the diagnosis of MS
within diagnostic criteria [3–5]. The so-called McDonald
criteria allow a diagnosis of MS based on MRI findings as
early as 3 months after the first clinical event without
further clinical relapses [6, 7]. Furthermore, in patients
presenting with a clinically isolated syndrome (CIS)
suggestive of MS, MRI has gained an important prognostic
value in terms of predicting the conversion to clinically
definite MS and long-term disability [8–10].
Currently, most of the MRI protocols for clinical and
research purposes are based on magnetic field strengths up
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to 1.5 T. Since the US Food and Drug Administration
approved magnetic field strength up to 8 T as having non-
significant risk [11], high field MRI systems are increas-
ingly incorporated into the clinical setting especially in the
field of neuroimaging leading to new possibilities and also
challenges in many directions.
The aims of this review are to provide a comprehensive
overview regarding the current level of knowledge and
evidence in terms of high field MRI in the diagnosis and
disease monitoring of MS and to discuss new directions of
high field MR imaging in MS.
High field MRI: technical considerations
and its implications for clinical applications
Moving to higher magnetic field strengths implies many
technical and physical changes including the signal-to-
noise ratio (SNR), tissue relaxation times, susceptibility,
Larmor frequency, chemical shift, B1 heterogeneity, and
radiofrequency power deposition. All the factors have
major consequences for the adaptation of imaging protocols
from lower to higher magnetic field strengths and the
implementation of new protocols in many different ways
[12, 13].
The SNR is considered to be approximately linearly
related to the magnetic field strength (S/N ~ B0). In other
words, a doubling of the magnetic field from 1.5 to 3 T
should double the signal. The increase in SNR is one of the
major advantages of MRI at higher field which can be
invested either in reducing scan time (e.g., by applying
parallel imaging techniques and/or variable flip angles,
longer echo trains) or in an increase of spatial resolution
(smaller voxel size) [14, 15].
Tissue relaxation times are substantially depending on
the static magnetic field (B0). The T1 (longitudinal)
relaxation time is significantly increasing when moving to
higher field strengths, increasing by approximately 40% in
the white matter at 3 T when compared to 1.5 T. This has
major consequences for gadolinium (Gd)-enhanced T1-
weighted sequences because this T1 prolongation at higher
fields pronounces the T1 shortening effect of Gd-based
contrast media leading to greater post-contrast signal of the
enhancing tissues [16]. Therefore, this higher T1 effect
might allow a lower dosage of contrast media at 3.0 T. The
change of the T2 relaxation time is less pronounced and
ranging up to 5% [12, 17].
On the other hand, T2* relaxation time and therefore T2*-
based sequences are remarkably influenced by higher B0
because of the substantial increase of susceptibility (ΔB ~
B0). Besides its negative consequences in terms of image
quality, the increase in susceptibility at higher fields can be
used for a better application of susceptibility-weighted
(perfusion) MR imaging and blood oxygen level-dependent
functional MRI (BOLD).
Chemical shift also increases proportionally with the
applied B0 (CS ~ B0). This offers great potentials for MR
spectroscopy due to an increased spectral resolution. The
increase of chemical shift in combination with higher SNR
offers the possibility for a better quantification of metabolite
concentrations especially in terms of sensitivity and repro-
ducibility [18, 19].
Major drawbacks of imaging at higher magnetic fields
are B1 heterogeneity and radiofrequency (RF) power
deposition. Especially the RF power deposition in terms
of the specific absorption rate (SAR) is of special interest
concerning safety aspects. SAR increases with the square of
B0 (SAR ~ B0
2). There are strict regulations of RF heating
in the tissue available and the SAR may not exceed 4 W/kg
within 15 min [20]. This limit is more likely to be reached
at higher magnetic fields especially by using pulse
sequences with a high SAR potential such as turbo(fast)-
spin echo (TSE) sequences. The implementation of parallel
imaging techniques and variable flip angles can be helpful
to address this issue [14].
Conventional high field MRI at 3 T in multiple sclerosis
Magnetic field strength-dependent lesion load measurement
The influence of the magnetic field strength on the
detection rate has already been of great interest since the
introduction of 1.5-T MRI scanners in the early 1990s.
Table 1 gives an overview of studies investigating the
possible influence of higher magnetic field strengths on the
detection of focal inflammatory lesions on CIS and MS
patients.
The first studies comparing magnetic field strengths of
0.5 and 1.5 T can be considered as inconclusive [21–23].
Two studies showed significantly higher lesion load
measurements at 1.5 T when compared to lower field
strengths especially in the infratentorial region [21, 22],
however, without any implications on this diagnosis of MS
according to the Poser criteria [24]. These results could not
be confirmed by the following study including a larger
cohort of 132 patients with suspected or definite MS [23].
Since the new generation of clinical high field scanners
mainly operating at 3 T has been incorporated into the
clinical setting, the question of possible field strength-
dependent different lesion load measurements in suspected
or definite MS revived again. The first evidence that the
new high field MRI generation provides higher lesion load
measurements in MS patients was brought up by an
intraindividual comparative study between 1.5 and 4 T.
Keiper et al. showed a 45% increase of T2 lesions using a
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4-T compared to a 1.5-T scanner [25]. This higher
sensitivity in the detection of focal MS lesions and/or
lesion volumes could be conclusively confirmed by the
subsequent studies comparing field strengths between 1.5
and 3 T including a total number 115 patients scanned with
MRI scanners of three different vendors [26–29]. The
increase in lesion numbers on T2/fluid-attenuated inversion
recovery (FLAIR) images ranged from 13% to 41.6%.
Concerning Gd-enhancing lesions the increase in sensitivity
amounts to 7.5–24%. The largest comparative study of 1.5
and 3 T including 40 patients presenting with a CIS
presented a subgroup analysis of different anatomic
locations. The authors found a pronounced increase of T2
and FLAIR lesion numbers in anatomic regions which are
important for the diagnosis of MS within diagnostic criteria
and prognostic purposes in terms of prediction of long-term
disability, namely in the juxtacortical, periventricular, and
of course in the infratentorial region (Fig. 1) [27]. Further
analysis revealed that based on a multisequence protocol
including a Gd-enhanced T1-weighted sequence, 27.5% of
those patients with more lesions on the 3 T fulfilled one
additional MRI criterion [30]. Acknowledging that these
MRI criteria have a strong predictive value concerning the
conversion to definite MS, patients are likely to receive a
different (worse) prognostic classification based on a 3-T
examination when compared to 1.5 T [8, 9]. However,
including neurological examinations (cerebrospinal fluid
(CSF) examinations, etc.) into the analysis, it became clear
that these higher lesion load measurements on 3 T do not
necessarily lead to different classifications according to the
clinical International Panel (IP) criteria for MS. Only one
single patient in this study received the diagnosis of
dissemination in space based on the 3 T but not on the
1.5-T examination [30]. Additionally, a short-term follow-
up study of this patient cohort clearly demonstrated that
higher lesion load measurements on 3 T versus 1.5 T do not
lead to an earlier diagnosis of MS [31], neither according to
the revised IP criteria nor to the recently introduced
Swanton criteria [7, 32].
In contrast to the high amount of data in terms of high
field MRI applications in the brain, almost no experience
exists regarding spinal cord imaging in MS using MRI field
strengths beyond 1.5 T. A recently published study is the
first demonstrating the applicability of 3-T MRI in MS
when compared to 1.5 T. The authors investigated 32
patients using a non-cardiac gated, single late echo T2-
weighted sequence at both field strengths. Although the
primary aim of this study was not a side-by-side compar-
ison of 3 T with 1.5 T in terms of lesion detectability, this
study showed no significant higher focal lesion load
measurements in the spinal cord on 3 T. Furthermore, the
T2 lesion load on 3 T did not correlate better to clinical
outcome measures such as disability when compared to T2
lesion load measurements obtained at 1.5 T [33].
Pulse sequences
According to recent published guidelines, the conventional
MRI protocol for patients with suspected or definite MS is
performed as a multisequence imaging protocol, including
axial proton density (PD)/T2-weighted, sagittal FLAIR, and
axial Gd-enhanced T1-weighted sequences [34]. These
guidelines are based on experiences made on magnetic field
strengths up to 1.5 T. At lower (0.5–1.0 T) and standard field
strengths (1.5 T), it became obvious that the sensitivity of
T2-weighted pulse sequences in the detection of focal MS
lesions is dependent on the anatomic region. T2-weighted
(turbo) spin echo (SE) sequences are characterized by a high
sensitivity in the detection of infratentorial lesions, whereas
the sensitivity is rather limited in the supratentorial brain,
Table 1 Overview of published studies investigating the possible influence of increasing magnetic field strengths on the detection of acute and
chronic inflammatory lesions in patients with CIS or definite MS.
Author, reference Field strengths tested (T) Patients; number Results
Schima et al. [21] 0.5, 1.5 CIS, definite MS; n=27 9.1% ↑ of T2 lesions
Lee et al. [22] 0.5, 1.5 Definite, suspected MS; n=132 No significant increase of lesion load
Filippi et al. [23] 0.5, 1.0, 1.5 Definite MS; n=20 Significant increase of T2 lesion volume
Keiper et al. [25] 1.5, 4.0 Definite MS; n=15 45% ↑of T2 lesions
Sicotte et al. [26] 1.5, 3.0 Definite MS; n=25 21% ↑of T1 Gd+ lesions, 54%, 10.7% ↑of T1 Gd+,
PD lesion volume
Wattjes et al. [27] 1.5, 3.0 CIS; n=40 7.5% ↑of T1 Gd+ lesions 13% ↑lesions, T2 and FLAIR,
Nielsen et al. [28] 1.5, 3.0 Definite MS, CIS; n=28 24% ↑of T1 Gd+ lesions, 26.5% ↑of FLAIR lesions per
patient
Bachmann et al. [29] 1.5, 3.0 Definite MS; n=22 41.6.% ↑lesions on FLAIR
MS multiple sclerosis, CIS clinically isolated syndromes suggestive of MS, T Tesla, Gd+ gadolinium-enhancing, FLAIR fluid-attenuated inversion
recovery, ↑ increase
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particularly in the juxtacortical and periventricular white
matter. FLAIR sequences provide higher lesion detection
rates in the juxtacortical and periventricular white matter but
lack sensitivity in the detection of lesions in the posterior
fossa and thalamus [35–39].
Moving to 3 T imaging, evidence is emerging that this
phenomenon of region-dependent lesion detectability is
somehow disappearing. An intraindividual comparative
study of T2-weighted TSE and FLAIR sequences at 3 T
including 49 patients presenting with CIS or definite MS
showed no significant changes concerning the sensitivity in
the detection of infratentorial lesions (Fig. 2) [40].
However, concerning the supratentorial brain, FLAIR
remains superior to the T2 TSE, especially regarding the
periventricular and juxtacortical regions. The underlying
reason of this finding is not well understood, since contrast
measurements revealed no significant differences between
both sequences in the posterior fossa. Perhaps the FLAIR
sequence, characterized by low SNR levels infratentorially
at 1.5 T, benefits most from the higher SNR provided by
3 T.
Given the fact that the FLAIR sequence at 3 T has the
highest overall sensitivity in the detection of inflammatory
lesions without relevant disadvantages regarding the poste-
rior fossa, the crucial question rises up whether a FLAIR
sequence at 3 T alone might be sufficient within a MS
imaging protocol. From our perspective, these questions
cannot be answered sufficiently yet because the current data
are only based on one study using a MRI device of one
vendor. Additional studies including MRI systems of other
vendors are necessary to validate these initial findings.
A new group of pulse sequences, which has been
recently introduced into the field of MS research, is double
inversion recovery (DIR) sequences. These sequences are
characterized by two inversion pulses achieving a simulta-
neous suppression of two different tissue types. Dependent
on the chosen inversion time, it is possible to simulta-
neously suppress the white matter and CSF (“gray matter
only”) or the gray matter and CSF (“white matter only”;
Fig. 3) [41]. The first approaches using a 2D DIR
application for brain imaging were quite promising regard-
ing many disease entities including inflammatory, vascular,
and neoplastic diseases. However, DIR at 1.5 T was never
established into the clinical routine probably due to the
relatively low SNR due to the application of two inversion
pulses, higher propensity of artefacts and longer scan time
[42, 43]. Recently, a 3D application at 1.5 T has been
introduced and evaluated concerning the detection of focal
gray matter lesions in MS patients [44]. This study shows
that 3D DIR is able to detect significantly more intracortical
lesions in MS, a lesion type seen abundantly in MS patients
but difficult to detect with conventional pulse sequences
such as PD/T2 and FLAIR [45]. Currently, DIR applica-
tions are used to detect and quantify cortical lesion load in
MS patients as well as correlate these measures with
subtypes, outcome measures, and clinical presentations of
MS patients [46, 47]. DIR applications at higher magnetic
field strengths may overcome major problems of DIR
applications at standard field strengths (1.5 T) such as low
SNR values and therefore long acquisition times. So far,
Fig. 1 Axial T2-weighted TSE (upper row) and FLAIR (middle and
bottom rows) sequences from patients with relapsing–remitting MS.
Compared to 1.5 T, the images based on 3-T examinations (right
column) show a higher conspicuity and identifiability of lesions
(arrows) in several anatomic regions of the brain especially the
infratentorial (upper row), periventricular (middle row), and juxtacort-
ical (bottom row) white matter. Please note also that the higher SNR of
3 T leads to a better visualization of small lesions (middle row, closed
arrow) which are likely to disappear in the noise of the white matter at
lower magnetic field strengths
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there is only one DIR study at 3 T available investigating
the diagnostic value in the detection of MS lesions [48].
DIR at 3 T seems to be the sequence with the highest
overall sensitivity in the detection of focal MS lesions when
compared to T2 TSE and FLAIR. DIR at 3 T detected
significantly more lesions than T2 TSE and FLAIR.
Regarding specific anatomic locations, DIR showed com-
parable results for the juxtacortical, mixed white matter–
gray matter and periventricular lesions in comparison to
FLAIR but significantly higher detection rates in the
infratentorial regions when compared to both T2 TSE and
FLAIR (Fig. 4). This finding makes this sequence partic-
ularly valuable for CIS patients since we know that
infratentorial lesions have a certain prognostic relevance
in terms of prediction of long-term disability [10]. There are
two good explanations for this higher sensitivity of 3 T DIR
concerning infratentorial lesions. First of all the contrast
ratio between lesions and normal-appearing white matter
(NAWM) was significant better for the DIR when com-
pared to the T2 TSE and FLAIR. Secondly, similar to the
experiences with FLAIR at 3 T, DIR might better take
advantage from the higher signal provided by 3 Tespecially in
the posterior fossa. Due to the better contrast of gray matter
versus white matter, many lesions classified as juxtacortical
on the FLAIR and T2 TSE sequences were (re)classified as
cortical or at least mixed gray matter–white matter lesions
which resulted in a sort of “reclassification phenomenon”
similar to experiences at 1.5 T (Fig. 5) [44, 48].
Fig. 3 Axial sections through
the supratentorial brain of a
healthy volunteer using a “dou-
ble inversion recovery” se-
quence at 3 T (measured voxel
size 3×1×1 mm). The cerebro-
spinal fluid as well as the white
matter is simultaneously attenu-
ated leading to a high contrast
and delineation between the
white matter and gray matter
Fig. 2 Axial FLAIR (top row)
and T2-weighted TSE (bottom
row) from a patient with relaps-
ing–remitting MS obtained at
1.5 T (left column) and 3 T
(right column) showing multiple
focal abnormalities in the cere-
bellum (arrows). At 1.5 T, we
can observe a higher conspicuity
of the lesion on the T2 TSE
sequences compared to the
corresponding FLAIR image.
Moving to 3 T, the conspicuity
and detection rate of focal MS
lesions is equal on both sequen-
ces. Please note also the higher
sensitivity using 3 T instead of
1.5 T, in particular on the
FLAIR images due to higher
SNR
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In addition, the higher SNR at 3 T can be invested into
“speed-optimized” pulse sequences without losing diagnostic
quality and sensitivity in the detection ofMS lesions (Fig. 6). A
study using a combination of T2-weighted fast spin echo,
variable flip angle refocusing and half-Fourier acquisition, and
parallel imaging achieved a reduction of the scan time from
2:02 min to 11 s (axial plane) and 3:24 min to 29 s (sagittal
plane), respectively, without a relevant impairment in sensi-
tivity. Still 88% of the 208 lesions detected on the standard T2
TSE sequence remained visible on fast T2 sequence [49].
3D applications are increasingly being used at standard
field strengths with the use of signal saving fast imaging
techniques such as variable flip angle refocusing [50–52].
Although higher field strengths might be able to provide
better basic conditions in terms of SNR, the implementation
of 3D acquisition techniques at higher magnetic fields
remains challenging. In the field of MS research, there is
one study available comparing whole brain 3D FLAIR and
T2 TSE sequences showing a better image quality compared
to 3 T [53].
Fig. 4 Axial sections of 3 T 2D
FLAIR (left column), T2-weight-
ed TSE (middle column), and
DIR (right column) sequences of
patients with relapsing–remitting
MS. Using DIR, more infraten-
torial lesions can be detected
when compared to FLAIR and
T2 TSE. Upper row: A focal
lesion in the right mesencephalon
touching the periaqueductal gray
matter (arrow) could be easily
detected on the DIR but was not
prospectively identified on the
corresponding FLAIR and T2
TSE images. Bottom row: A
focal lesion in the right cerebel-
lum is clearly visible on the DIR
sequence with high signal inten-
sity (arrow) but not visible on
the corresponding FLAIR and T2
TSE images
Fig. 5 Transverse sections of a 2D TSE (left), FLAIR (middle), and
DIR (right) through the supratentorial brain of a MS patient showing
multiple focal lesions in the deep white matter, juxtacortical white
matter, and also lesion located partially or totally in the gray matter.
Please note that based on DIR imaging, it is much easier to
differentiate between those lesions located in the juxtacortical white
matter (open arrow) and those lesions which are at least partially
located in the gray matter (closed arrows)
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Quantitative MRI methods
The lack of correlation between conventional MRI
findings in terms of T2 lesion load and clinical outcome
measures, the so-called clinico-radiological dissociation
has urged the development of several quantitative MRI
methods including MR spectroscopy, diffusion tensor
imaging, and magnetization transfer imaging [54–56]. Of
special interest are these methods in quantifying disease
burden in the normal-appearing brain tissue, particularly in
CIS patients in order to get additional prognostic informa-
tion [54, 57, 58].
Among those quantitative methods, 1H-MR spectrosco-
py benefits the most from the advantages provided by the
higher magnetic field strengths [18, 19, 59, 60]. Conse-
quently, the most experience concerning quantitative MRI
methods in MS patients has been collected for 1H-MR
spectroscopy so far.
1H-MR spectroscopy
1H-MR spectroscopy (1H-MRS) is one of the best estab-
lished quantitative MRI methods allowing the assessment
and quantification of metabolic changes in lesions and the
normal-appearing brain tissue (normal-appearing white
matter; normal-appearing gray matter) of patients with
CIS or definite MS [54]. In MS, two major metabolites
are of special interest: the first one, the N-acetyl moiety
(tNAA), a maker of neuronal viability. The second metab-
olite, myo-inositol (mIns), is mostly located in astroglial
cells and serves as a marker of glial cell activity [61–64].
In demyelinating diseases, particularly in patients with
definite MS, decreased tNAA as well as increased mIns
concentrations and therefore axonal damage and increased
glial cell activity can be observed in lesions as well as in
the normal-appearing brain tissue [65–69]. In patients
presenting with CIS, however, significant axonal damage
could only be observed in whole brain analysis including
normal-appearing brain tissues and lesions but not in the
NAWM alone [70]. In contrast, mIns concentrations seem
to be increased in the NAWM of CIS patients [71, 72].
All these studies dealing with metabolic alterations in MS
and CIS patients were performed at field strengths up to
1.5 T.
1H-MRS at higher field strengths is characterized by a
better spectral separation due to a significant increase in
chemical shift particularly for the C4–C6 multiplet of mIns,
which at 1.5 T partly overlaps with the glutamate and
glutamine (Glx) signals. Therefore, the combination of an
improved spectral separation with an increase in SNR
provides a more accurate and reproducible (absolute)
quantification of metabolites [18, 73]. Figure 7 gives an
example of the altered appearance of the spectrum.
Recently published single voxel 1H-MRS studies in CIS
patients including an optimized acquisition protocol for
tNAA and mIns (short and long echo time acquisition)
demonstrated that axonal damage is already present in CIS
patients not fulfilling the criteria for definite MS [74]. A
significant increase of mIns could be observed in patients
with an early disease course of relapsing–remitting MS but
not in patients presenting with a CIS. However, those CIS
patients who converted to definite MS after short-term
Fig. 6 Axial conventional T2-weighted images within the supra-
tentorial brain of a 41-year-old female with relapsing–remitting MS:
on the left side a conventional T2 TSE (acquisition time 2:02 min), on
the right side a T2 TSE sequence with variable flip angle refocusing
and half-Fourier acquisition (acquisition time 0:11 min). Even small
focal lesions could be detected on the speed-optimized T2 TSE
sequence (arrow). For detailed sequence parameters, see Lutterbey et
al. [49]
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follow-up showed almost significantly higher absolute
concentrations of mIns when compared to healthy controls
whereas the non-converters did not (20.2% versus 1.9%
increase of mIns). Axonal damage also seems to have
prognostic relevance in terms of predicting the conversion
to definite MS in CIS patients. MS converters showed
evidence of axonal damage in terms of tNAA decrease
compared to healthy controls, while non-converters did not
[75]. Regarding prognostic purposes, these results obtained
at 3 T are in line with 1.5-T results demonstrating
significantly lower tNAA concentration in patients convert-
ing to definite MS within 1 year and higher mIns
concentration in converters within 3 years time [76].
The “clinico-radiological dissociation” in terms of the
non-correlation of lesion load measurements on conven-
tional MRI and clinical outcome measures on one hand and
quantitative MRI measures on the other hand can also be
observed on magnetic field strengths beyond 1.5 T.
Metabolic changes measured with 1H-MRS at 3 T did not
correlate with lesion load on conventional MRI finding in
terms of fulfilled MRI criteria. Metabolic alterations in the
NAWM of CIS patients measured by high field 1H-MRS
which do have a predictive value concerning the conversion
to definite MS do not correlate with the fulfilled diagnostic
imaging criteria measured by conventional MRI. Even the
classification according to the clinical IP criteria in terms of
lesion dissemination in space does not correlate with
metabolic changes in the NAWM of CIS patients [77].
This once more stresses the fact that changes in the normal-
appearing brain tissue and lesion load visible on conven-
tional MRI are developing in different ways and contribute
diversely to the natural history of the disease. We have to
further investigate cautiously whether advanced MRI
methods at higher field strengths such as 1H-MRS may
provide better information concerning the risk of conver-
sion from CIS to definite MS and should be used
exclusively or in combination with conventional MRI.
Besides the established metabolites including tNAA,
mIns, choline (Cho), and total creatine (tCr), further
metabolites such as the constituents of Glx signal are
gaining certain interest and are beginning to fill voids in the
current understanding of pathophysiological processes in
MS. Standard field strengths have major difficulties in the
(absolute) quantification of Glx. Due to the higher SNR
and improved spectral separation at higher fields, an
accurate and reproducible quantification of Glx becomes
realistic. A recent study applying a TE-averaged PRESS
technique at 3 T showed significantly increased Glutamate
concentration in active lesions and also in the NAWM,
suggesting that neuro-toxicity expressed by higher concen-
tration of glutamate might play a substantial role in the
inducement of axonal damage and therefore clinical
disability [78, 79].
Moreover, 1H-MRS at 3 T also offers chances to detect
and quantify metabolic changes of CNS regions very
important for diagnostic and prognostic purposes, which,
however, are difficult to evaluate at lower field strengths
because of lower SNR values and the need of high spatial
resolution imaging such as the infratentorial brain and the
spinal cord [80].
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Fig. 7 1H-MRS spectrum at 1.5 T (left) and 3 T (right) obtained from
the NAWM of a patient presenting with a CIS suggestive of MS.
Please note the change in the appearance at 3 T, especially the signal
increase and the better separation from Glx for the C4–C6 multiplet of
mIns at 3.63 ppm. NAA N-acetylaspartate, tCr total creatine, Cho
choline, Ins (myo)inositol, Glx summation of glutamate and glutamine
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Diffusion tensor imaging
Diffusion-weighted imaging in general and diffusion tensor
imaging (DTI) in particular have been increasingly applied
in the evaluation of pathological changes in MS. Similar to
1H-MRS, DTI is a promising quantitative MRI method for
the detection of abnormalities in the normal-appearing brain
tissue. It has been consistently shown that altered diffusion
in terms of a decreasing fractional anisotropy and increas-
ing mean diffusivity can be observed in lesions and also in
the normal-appearing brain tissue [55, 57, 81].
From the technical point of view, DTI remains a quite
challenging method concerning the image acquisition and
reproducibility especially across different sequences and
scanners (different vendors and magnetic field strengths)
[82]. Most DTI sequences are based on single shot echo
planar imaging sequences in order to achieve a fast image
acquisition. However, this type of sequence is characterized
by substantial drawbacks such as a proneness to geometric
distortions, limited SNR, and low spatial resolution. High
field MRI applications can overcome many of these
problems due to the increase of SNR. These higher SNR
values can be traded off in a different way: First of all, it
allows an image acquisition in a faster way or with a higher
spatial resolution (or a combination of both). Secondly, the
higher SNR offers the chance to apply parallel imaging
techniques which once again can reduce the scan time (due
to shorter echo trains), but more importantly also reduces
geometrical distortions which consequently lead to a better
image quality [83–85]. The higher SNR can also be
invested into higher spatial resolution which offers new
possibilities for “fiber tracking” applications.
Despite the obvious advantages of DTI at 3 T in
comparison to lower field strengths, the number of published
applications inMS is rather limited so far [86–89]. The results
of studies performed at 3 T are not likely to differ
substantially from those obtained at lower field strengths,
3 T DTI might offer a greater perspective of (multipara-
metric) MRI research involving certain anatomic regions
which are more difficult to investigate at lower fields such as
gray matter structures [86, 87].
Functional MRI
Susceptibility-weighted imaging (SWI) and BOLD func-
tional MRI (fMRI) are applications which benefit the most
from the increased sensitivity to susceptibility differences
provided by higher magnetic fields. The BOLD signal
increases significantly with the magnetic field strength and
therefore allows a better depiction of certain areas of
activation which cannot be visualized at standard field
strengths.
In MS, fMRI studies of multiple cognitive and motor
networks have already shown that abnormal activation and
the presence of adaptive properties, the so-called phenom-
enon of brain plasticity, are already present in the early
stages of MS. There have been multiple approaches
reported to describe activation patterns and connectivity
networks in MS patients across all different stages and
disease courses [4, 90, 91]. For instance, for performing
simple motor tasks with the right hand, it could be shown
that there is an additional activation of the contralateral
primary sensorimotor cortex and supplementary motor area.
Although the advantage of fMRI based on BOLD contrast
at higher fields is quite obvious, the experiences are based
on a rather limited number of patients. Using fMRI
methods at higher magnetic field strengths, it might be
possible to detect new activation patterns and connectivity
networks such as those involving the cerebellum and mirror
neuron system which cannot easily be evaluated at standard
field strengths [92, 93].
Ultra-high field MRI
High field MRI applications beyond 4 T are currently
considered as ultra-high field MRI. Driven by the success
of whole body high field MRI applications at 3 T and the
update of the FDA approval concerning field strengths up
to 8 T, we are currently witnessing a rapid increase of
installations of ultra-high field MR systems worldwide.
Most of them are whole body scanners operating at 7 T
which can be used for post-mortem as well as in vivo
applications. However, despite the convincing possibilities
in terms of increased SNR, there are substantial challenges
such as SAR, inhomogeneities of the magnetic field and the
effect on tissue relaxation times. Most of the problems have
not been solved so far and remain challenges in particular
for in vivo imaging applications.
In MS, ultra-high field MRI was initially used to further
visualize and characterize certain aspects of MS pathology at
submillimeter resolutions and correlate these findings with the
corresponding histopathological results in post-mortem spec-
imen of the brain and the spinal cord. Later on, with the advent
of clinical whole-body ultra-high field MRI systems, in vivo
studies tried to establish imaging protocols in order to
investigate the feasibility of in vivo ultra-high field MR
imaging in MS patients despite the technical challenges.
Spinal cord
Lesions in the spinal cord are frequently observed in
MS patients and are already present in early stages of the
disease [7, 94, 95]. In contrast to experiences in brain
imaging, high field MRI applications up to 3T failed to
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demonstrate a higher sensitivity in the detection of spinal
cord abnormalities. High resolution post-mortem MR
imaging studies at 4.7 T convincingly showed a high
sensitivity in the detection of focal and rather diffuse
abnormalities of the spinal cord superior to conventional
MRI at 1.0 T with a high grade of correlation regarding the
corresponding histopathological results. Furthermore, quan-
titative MRI methods at 4.7 T such as the measurement of
T1 relaxation times and MT ratios showed a high
correlation with demyelinating features on the semi-
quantitative histopathological myelin analysis [96–99].
Brain
Several high resolution post-mortem MRI studies have
already demonstrated the good correlations between imag-
ing findings and histopathological results. Nowadays, there
is definitely a need to focus on special pathological features
of the disease using ultra-high field MRI. One of the most
intriguing imaging and pathological feature of the disease is
the detection of cortical abnormalities. Given the fact that
conventional MRI in vivo lacks a sufficient sensitivity in
visualizing cortical changes, it would be interesting to
know whether higher field strengths can overcome this
problem. However, the first results using 4.7 T showed that
sensitivity in the detection for cortical lesions remained
poor when compared to 1.5 T. Moreover, it has been shown
that sensitivity is dependent on the special type of cortical
lesions [100]. Moving to field strengths up to 8 T, there is
preliminary evidence that the sensitivity might sufficiently
increase [101]. However, these findings are based on a very
small number of specimens and need to be further
validated.
The number of in vivo studies using ultra-high field MRI
in MS is very limited so far. Currently, there are no
published studies available demonstrating the advantages of
ultra-high field MRI in comparison to 1.5 or 3 T. The first
in vivo applications of 7 T MRI in MS were mainly focused
on a high resolution imaging of special features of MS
pathology such as the perivascular distribution and micro-
vasculature of MS lesions (Fig. 8), a phenomenon which
already had been demonstrated at lower field strengths
[102, 103].
An intriguing SWI application of ultra-high field MRI at
7 T which goes beyond the visualization of the microvas-
culature structures of MS pathology is the implementation
of a quantitative MRI method of the local field shift which
is based on magnetic susceptibility-shifted compounds of
paramagnetic structures such as iron [104, 105]. Since iron
plays an important role in acute and chronic inflammatory
processes, this technique clearly demonstrated the increased
iron deposition in certain structures of MS patients such as
the basal ganglia. Moreover, it improves the detection rate
of lesions and enables us to visualize in vivo special
pathological features such as the iron-rich rim of MS
lesions containing iron containing macrophages without
injection of any contrast media.
Summary and future directions
As illustrated in this review, during the past century,
overarching research activities have been performed in the
area of high field MRI, generally but also specifically in the
field of MS research. The question provocatively asked in
the title of this article whether higher field leads to higher
Fig. 8 Axial high resolution T2-weighted image (measured voxel size
0.7×1×2 mm; repetition time 4,969 ms, echo time 80 ms) at 7 T
obtained from a patient with relapsing–remitting MS (left side)
demonstrating the perivascular distribution of focal MS lesions
(arrows). The perivascular distribution pattern can be confirmed by
the corresponding (modified) susceptibility-weighted image (measured
voxel size 0.35×0.45×0.60 mm) on the right side
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yields can be partially answered with yes. The current
generation of high field MRI scanners provides higher
sensitivities in the detection of focal abnormalities in the
brain, allows the implementation of new pulse sequences
such as DIR with improved SNR and positive effect on
lesion conspicuity and detectability, delivers substantial
improvements for 1H-MRS in terms of an more accurate
and reproducible metabolite quantification, and offers new
possibilities for fMRI. However, some important issues
have still to be addressed.
One challenging task will be to reveal the potential of
high field MR imaging to detect spinal cord abnormalities
in MS. Although post-mortem high resolution imaging
studies are suggesting the possibility of an increased
detection of spinal cord abnormalities, in vivo MRI of the
spinal cord remains sophisticated due to many artifacts
including CSF and vessel pulsation. In combination with
technical challenges, this might be the reason that there are
almost no data available so far dealing with the applicabil-
ity of in vivo high field MRI in the spinal cord of MS
patients. Additionally, it is doubtful whether in vivo high
field MRI might actually lead to an increased sensitivity in
the detection of spinal cord abnormalities. On the other
hand, the higher SNR might lead to re-implementation of
sequences such as inversion recovery with a low sensitivity
at standard field strengths.
Most of the research has focused on conventional brain
imaging in MS, and across all studies, it has been
conclusively shown that brain imaging benefits most from
the higher field strengths. However, there are still important
questions to address. One of these deals with the visuali-
zation of cortical abnormalities. It is important to know
whether 3-T MRI in vivo using DIR is able to detect more
cortical abnormalities than 1.5 T does. In a second step, we
have to try to implement DIR sequences also into in vivo
ultra-high field (7 T) MRI protocols and attempt to further
increase the sensitivity regarding the detection of cortical
abnormalities because these changes are a hallmark of MS
pathology. Additionally, higher magnetic fields might lead
to a better detection and classification of diffuse abnormal-
ities in MS, a radiological feature which is probably
underrated in many ways so far.
New more specific contrast media are coming up in the
in vivo detection of active MS pathology and are currently
evaluated in terms of standard magnetic field strengths.
Especially substances based on iron oxide such as ultra-small
particles of iron oxide indicating a cellular inflammation
mediated by macrophages might benefit substantially from
the higher magnetic fields using special imaging techniques
such as susceptibility-weighted imaging.
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